Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Suggestive evidence for bromocriptine-induced pleurisy

R J Klaassen1, R J Troost, G T Verhoeven

  • 1Department of Internal Medicine I, University Hospital Dijkzigt, Netherlands.

The Netherlands Journal of Medicine
|June 1, 1996
PubMed
Summary

Bromocriptine, used for Parkinson's disease, may cause pleurisy with pleural thickening. Stopping the drug improved symptoms and labs, highlighting its potential role and the need for monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EndoBridge 2024: pearls and highlights.

Hormones (Athens, Greece)·2025
Same author

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).

Pituitary·2025
Same author

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).

Pituitary·2024
Same author

EndoBridge 2023: highlights and pearls.

Hormones (Athens, Greece)·2024
Same author

Correction: consensus on criteria for acromegaly diagnosis and remission.

Pituitary·2023
Same author

Consensus on criteria for acromegaly diagnosis and remission.

Pituitary·2023

Area of Science:

  • Pulmonology
  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease management often involves dopamine agonists like bromocriptine.
  • Long-term medication use can present with unexpected adverse effects.
  • Pleurisy, inflammation of the lung lining, can have various etiologies.

Observation:

  • A patient on long-term bromocriptine therapy developed pleurisy with bilateral pleural thickening.
  • The condition caused severe restrictive pulmonary dysfunction.
  • Laboratory findings included elevated ESR, polyclonal hypergammaglobulinaemia, acute phase reactants, and anemia.

Findings:

  • Bromocriptine withdrawal led to marked clinical and laboratory improvement.
  • Pulmonary function decline halted, but pleural thickening persisted, suggesting fibrosis.

Related Experiment Videos

  • Despite suggestive clinical evidence, in vitro tests for immunopathogenicity were negative.

    • Implications:

    • Bromocriptine is a potential cause of drug-induced pleurisy.
    • Early drug cessation is crucial to prevent irreversible pulmonary impairment.
    • Regular monitoring of patients on long-term bromocriptine is recommended.